1. Introduction {#s0005}
===============

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer by incidence ([@bb0555]), and a leading cause of cancer-related death ([@bb0040]). HNSCC displays substantial variability in prognosis and response to standard therapies ([@bb0040]), which may reflect underlying etiological and molecular heterogeneity. For example, it is now well-understood that HNSCCs caused by high risk strains of human papilloma virus (HPV) are molecularly distinct from HPV negative (HPV −) HNSCCs and that they have better prognosis and therapy response ([@bb0650], [@bb0330]). Smoking is the major risk factor for HPV − HNSCC, causing genetic mutations in tumor suppressor genes including TP53 ([@bb0130], [@bb0625]). Alcohol consumption is a modest risk factor for HNSCC and is thought to increase risk particularly in smokers ([@bb0125]). However, there is an increasingly recognized incidence of HPV − HNSCCs in individuals with no smoking history, indicating that etiological factors other than smoking and HPV exist ([@bb0230], [@bb0220], [@bb0090], [@bb0600], [@bb0390], [@bb0480], [@bb0335], [@bb0340], [@bb0060], [@bb0445], [@bb0485], [@bb0605]). HNSCCs lacking these classic risk factors, referred to as 'atypical' HNSCCs, are usually oral squamous cell carcinomas (OSCCs), occur with higher relative frequency in women (particularly women of low socioeconomic status ([@bb0105], [@bb0110])) than smoking-related HNSCCs, and may be increasing in incidence ([@bb0090], [@bb0480], [@bb0335], [@bb0340], [@bb0315]). While molecular differences between HPV positive (HPV +) and HPV − HNSCC have been described in recent years ([@bb0375], [@bb0170], [@bb0530]), molecular attributes of smoking-related, atypical, or other etiological HNSCC subgroups have not been established.

Unsupervised clustering of molecular data, such as gene expression or DNA methylation, provides a method of classifying intrinsic subtypes within cancer populations ([@bb0235], [@bb0255]). Identification of cancer subtypes has provided insight into the etiological factors underlying molecular and clinical heterogeneity in other cancers and has provided clinical biomarkers to predict prognosis and subtype-specific therapeutic response ([@bb0235], [@bb0255], [@bb0400]). Four HNSCC subtypes have been identified by clustering of gene expression data ([@bb0100], [@bb0320], [@bb0355], [@bb0630]). We have previously reported our identification of five HNSCC subtypes based on clustering of integrated DNA methylation and gene expression data from 310 HNSCCs from The Cancer Genome Atlas (TCGA) study ([@bb0205]).

DNA methylation, i.e., the covalent addition of methyl groups to CpG dinucleotides to form 5-methylcytosine (5mC), is the best-known epigenetic mechanism of transcriptional regulation, and is widely altered in virtually all cancers, as an early and potentially causative event ([@bb0300], [@bb0165]). Typical patterns of abnormal methylation in cancer include silencing of tumor suppressor genes by aberrant methylation (hypermethylation) of gene promoters, particularly at promoter CpG islands, as well as general loss of DNA methylation overall (hypomethylation), potentially resulting in genomic instability and reactivation of oncogenes ([@bb0300], [@bb0295]).

DNA methylation patterns are altered by smoking ([@bb0550], [@bb0410]), HPV ([@bb0375]) and age ([@bb0655]), and may therefore capture important information about etiological drivers of HNSCC. Moreover, cancer molecular subtypes tend to differ depending on the molecular analyte (such as DNA methylation and gene expression) used for clustering ([@bb0235]). Therefore, we have investigated the clinical, etiological, and molecular attributes of DNA methylation HNSCC subtypes in the complete set of TCGA HNSCC patients (n = 528), in order to gain insight into the factors that drive intertumoral heterogeneity.

We have reproduced five DNA methylation subtypes, which differ from the reported gene expression subtypes, and which more clearly segregate with etiological subgroups defined by HPV status and smoking. As most research into molecular heterogeneity has focused on differences between HPV + and HPV − HNSCC, we have focused primarily on heterogeneity within HPV − HNSCC. Most importantly, we identified two atypical HNSCC subtypes, including a molecularly distinct subtype that is reproducible in additional data sets, providing molecular classification for atypical HNSCC.

2. Methods {#s0010}
==========

2.1. Data processing {#s0015}
--------------------

Preprocessed TCGA DNA methylation data (generated using the Illumina Infinium HumanMethylation450 BeadChip array), gene expression data (generated by RNA sequencing), somatic point mutation data (generated using genome sequencing), DNA copy number data (generated by microarray technology) and clinical data were downloaded using the Firehose pipeline ([@bb0515]). Preprocessing for these data sets was done according to the Firehose TCGA pipelines described elsewhere ([@bb0515]).

Mutation data was accessed as Mutation Analysis reports, generated using MutSig CV v2.0 ([@bb0350]). For analysis of individual significantly mutated genes (e.g., CASP8, NSD1), mutations predicted as silent by MutSig CV were removed. For analysis of smoking mutation signatures, G \> T & C \> A transversions in all genes, including silent mutations, were included. DNA copy number data was accessed as Copy Number reports, generated using GISTIC 2.0 ([@bb0420]).

Additional data preprocessing of gene expression and DNA methylation data was done as follows: Genes and patients with \> 10% missing values for gene expression, and \> 20% missing values for DNA methylation, were removed. All remaining missing values were estimated using KNN impute ([@bb0610]). TCGA data were generated in batches, creating a batch effect for most data sets. Batch correction was done using Combat ([@bb0290]).

TCGA assignments for gene expression subtypes for 279 HNSCCs were derived from [@bb0565]. Assignments for HPV and other viral infection status for 304 HNSCCs was derived from [@bb0575], a recent study in which TCGA cancers were screened for expression of viruses in RNA-Seq data. We compared these HPV status assignments with those derived using in situ hybridization and P16 staining for smaller numbers of samples in standard TCGA clinical data: While HPV status determined by RNA-Seq analysis was consistent with HPV status defined by in situ hybridization, as reported ([@bb0575]), three HNSCCs that were found HPV − based on RNA-Seq detection were found HPV + based on p16 staining. However, p16 staining is an indirect method of HPV detection, and is considered less accurate than measurement of HPV RNA expression ([@bb0430]), therefore RNA-Seq analysis was used as a primary measure of HPV status in our analysis.

Oral squamous cell carcinomas were defines as cancers of the alveolar ridge, buccal mucosa, floor of mouth, hard palate, oral cavity, oral tongue, and oropharynx.

2.2. Clustering of DNA methylation data {#s0020}
---------------------------------------

Methylation of neighboring CpG sites tends to be highly correlated. To reduce multiple testing of highly correlated CpG probes, and to reduce the dimensionality of the methylation array data, probes for each gene were clustered using hierarchical clustering with complete linkage, and average methylation was calculated for each CpG cluster.

2.3. Classification of abnormally methylated genes {#s0025}
--------------------------------------------------

MethylMix was applied to CpG cluster data to systematically identify CpG clusters (referred to as 'MethylMix genes') that are abnormally methylated in cancer versus normal tissue, where DNA methylation is inversely associated with RNA expression of the same gene, using beta-mixture models, as previously described ([@bb0200]). For each MethylMix gene, MethylMix ascribes either normal or abnormal (hypomethylated or hypermethylated) DNA methylation states to each patient, providing lists of hypermethylated and hypomethylated genes for each cancer.

2.4. Consensus clustering of MethylMix driver genes {#s0030}
---------------------------------------------------

Unsupervised Consensus clustering was applied to MethylMix gene DNA methylation state data for 528 HNSCCs, to identify robust patient clusters (Putative subtypes). Consensus clustering was performed using the ConsensusClusterPlus R package ([@bb0645]), using 1000 rounds of k-means clustering, with a maximum of k = 10 clusters. Selection of the best number of clusters was based on visual inspection of plots provided in the ConsensusClusterPlus output.

2.5. Survival analysis {#s0035}
----------------------

To test for overall survival differences between the MethylMix subtypes, the chi-square statistic test for equality was used to compare survival curves for each subtype. Survival data was censored at five years, to exclude deaths that were not HNSCC-related.

2.6. Application of gene expression signatures {#s0040}
----------------------------------------------

The xenobiotic metabolism gene signature included 95 human genes annotated to the term 'xenobiotic metabolic process' (GO:0006805), derived from the AmiGO web application ([@bb0075]). Wilcoxon rank sum tests were used to test for differences in mean expression of these genes between MethylMix subtypes.

2.7. Development of a gene expression classifier to predict the CIMP-Atypical subtype {#s0045}
-------------------------------------------------------------------------------------

Prediction Analysis of Microarrays (PAM) was used to develop a gene expression classified to predict the CIMP-Atypical subtype, as previously described ([@bb0595]). PAM analysis uses a nearest shrunken centroids machine learning method that predicts the class (MethylMix subtype) of an individual based on the squared distance of the gene expression profile for that individual to the centroids of known CIMP-Atypical and other subtype patient groups. Shrinkage is used to select the optimum number of genes for class prediction, such that the model selects only a subset of genes to develop the centroids. We first used PAM in combination with 10-fold cross validation to determine the ability of the gene expression data to predict the CIMP-Atypical subtype within TCGA data. For each fold of cross validation, the PAM model was trained on 90% of patients and assigned class probability for belonging to the CIMP-Atypical subtype to the each of the remaining 10% of patients based on the distance of the patient to its closest centroid. We used the area under the ROC curve (AUC) to evaluate the performance of the model in accurately predicting the class of samples.

We applied this gene expression classifier signature to two independent gene expression data sets to classify them into either a 'Predicted CIMP-Atypical' group or a 'Not predicted CIMP-Atypical' group, using gene expression data for the top 25% most varying genes (i.e., with the highest mean absolute deviation). These included GSE65858 ([@bb0640]) which included 253 primary HNSCCs, with gene expression measured using the Illumina HumanHT-12 V4.0 expression beadchip, and GSE39366 ([@bb0630]), which included 139 primary HNSCCs, with gene expression measured using an Agilent-UNC-custom-4X44K array. Normalized gene expression data for these data sets was accessed. To classify a new sample, its distance is calculated to each of the centroids by using the weights as an inner product, and the sample is classified to its closest centroid. We only used classification results when probabilities were \> 60% or \< 40%, excluding low confidence assignments for the remaining borderline individuals from analyses.

2.8. Inference of tumor associated leukocyte levels {#s0050}
---------------------------------------------------

CIBERSORT was applied to gene expression (RNA-Seq) data to infer the levels of specific TAL types, as previously described ([@bb0455], [@bb0195]). Only patients for with estimation p-values \< 0.05 (Indicating high confidence TAL estimation) were included in downstream analyses.

2.9. Identification of genes associated with the CIMP-Atypical subtype {#s0055}
----------------------------------------------------------------------

SAM analysis ([@bb0620]) was used to identify genes that were overexpressed and underexpressed in the CIMP-Atypical subtype relative to other subtypes (combined).

2.10. Functional gene set enrichment analysis {#s0060}
---------------------------------------------

Functional gene set enrichment analysis (GSEA) was carried out using MSigDB ([@bb0570]), selecting all 18,026 gene-set libraries for comparison with the input prognostic gene-set. The top 100 most enriched gene sets were visualized as a network map generated using Enrichment Map as a plugin for Cytoscape ([@bb0280]).

3. Results {#s0065}
==========

3.1. Unsupervised clustering of HNSCC patients {#s0070}
----------------------------------------------

To investigate possible sources of clinical and biological heterogeneity in HNSCC, we subtyped 528 HNSCC cases according to their profiles of epigenetically deregulated genes. We applied MethylMix ([@bb0200]) to whole genome DNA methylation and gene expression data, to identify abnormally methylated genes in HNSCC, i.e., genes that are hypermethylated or hypomethylated in all or a subgroup of HNSCCs relative to normal adjacent tissue and where this methylation is associated with altered RNA expression. MethylMix identified 2227 differentially methylated 'MethylMix genes' ([Supplementary Table 1](#ec0010){ref-type="supplementary-material"}, see methods for definition of MethylMix genes). MethylMix assigned each cancer to a categorical DNA methylation class (hypermethylated, hypomethylated or normal-like) for each gene, with differential methylation (DM) values indicating the direction and mean difference in methylation between cancer and normal tissue. We then performed Consensus clustering to DM value data to cluster HNSCCs into clusters or putative intrinsic subtypes.

To identify the optimum number of HNSCC clusters, consensus clustering was performed iteratively with incremental numbers of clusters, and the cluster number at which consensus was strongest was chosen. Consistent with our previous report ([@bb0205]), greatest consensus was achieved for 5 clusters (Supplementary Fig. 1). These clusters were considered putative subtypes, including one HPV + subtype (subtype 4), and four HPV − subtypes ([Fig. 1](#f0005){ref-type="fig"}, [Supplementary Table 2](#ec0015){ref-type="supplementary-material"}). We named these subtypes the 'Non-CIMP-Atypical', 'NSD1-Smoking', 'CIMP-Atypical', 'HPV +', and 'Stem-like-Smoking' subtypes, according to their most distinctive clinical and molecular attributes.

3.2. MethylMix subtypes differed from TCGA gene expression subtypes {#s0075}
-------------------------------------------------------------------

Four gene expression subtypes have been identified for HNSCC, each associated with distinct etiological HNSCC features ([@bb0100], [@bb0320], [@bb0355], [@bb0630]). We assessed the distribution of these expression subtypes within our MethylMix subtypes, based on assignments by the TCGA study for 279 cancers ([@bb0355]) (Supplementary Fig. 2). While our HPV + subtype was comprised almost entirely of the Lawrence et al. designated HPV-related 'Atypical' (AT) gene expression subtype, all other MethylMix subtypes were comprised of mixtures of multiple gene expression subtypes. Notably, the 'Mesenchymal' (ME) expression subtype distributed almost evenly between four MethylMix subtypes. This indicates that integrated DNA methylation and expression subtypes capture unique sources of molecular heterogeneity.

3.3. Identification of a single HPV positive subtype {#s0080}
----------------------------------------------------

A recent study inferred infection status for HPV and other human viruses by measuring expression of viral transcripts in tumor RNA-Seq data ([@bb0575]). We utilized this, the most complete data source in terms of patient numbers, as a measure of HPV status. 97% of patients within the HPV + MethylMix subtype were positive for either HPV16 (89% (32/36)) or HPV33 (8% (3/36)), compared with 0--7% of other subtypes ([Fig. 1](#f0005){ref-type="fig"}, Supplementary Fig. 3, [Table 1](#t0005){ref-type="table"}). The HPV + subtype was enriched for classic features of HPV + HNSCC, including enrichment for base of tongue and tonsil cancer (Supplementary Fig. 4, [Table 1](#t0005){ref-type="table"}), few smokers ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}), and the lowest overall mutation burden ([Table 1](#t0005){ref-type="table"}), with lack of *TP53* and *CDKN2A* mutations ([Fig. 1](#f0005){ref-type="fig"}, Supplementary Fig. 5). The HPV + subtype was associated with significantly improved overall survival compared with other subtypes (Supplementary Fig. 6), consistent with previous reports ([@bb0535], [@bb0015]). Our MethylMix subtypes segregated more clearly with HPV status than the TCGA gene expression subtypes: While most HPV + HNSCCs occurred within the AT gene expression subtype, 57% HNSCCs within this subtype have had no detected virus (Supplementary Fig. 7). This suggests that integrated DNA methylation and gene expression is a more accurate biomarker of HPV status than gene expression alone and demonstrates that our MethylMix subtypes represent biologically meaningful groups. Moreover, separation of MethylMix subtypes according to HPV status allowed us to unambiguously investigate variability of other factors, such as smoking, between HPV − subtypes, independent of HPV.

3.4. Identification of smoking-related and atypical subtypes of HPV − HNSCC {#s0085}
---------------------------------------------------------------------------

Two HPV − subtypes, the NSD1-Smoking and Stem-like-Smoking subtypes, were overrepresented for current and recent former smokers (\< 15 years), compared with the Non-CIMP-Atypical and CIMP-Atypical subtypes ([Fig. 2](#f0010){ref-type="fig"}a). Consistently, the NSD1-Smoking and Stem-like-Smoking subtypes had the highest overall mutation burden, primarily driven by significantly higher levels of C \> A and G \> T transversions, the primary mutation signatures associated with smoking ([@bb0240], [@bb0565], [@bb0215], [@bb0305], [@bb0135], [@bb0245]) ([Fig. 2](#f0010){ref-type="fig"}b, [Table 1](#t0005){ref-type="table"}). These subtype also displayed higher mean numbers of copy number aberrations ([Fig. 2](#f0010){ref-type="fig"}c, [Table 1](#t0005){ref-type="table"}), also associated with smoking intensity in cancer ([@bb0270]). Moreover, the NSD1-Smoking and Stem-like-Smoking subtypes had higher levels of expression of xenobiotic metabolism genes ([Fig. 2](#f0010){ref-type="fig"}d, [Table 1](#t0005){ref-type="table"}), a measure of cellular response to xenobiotic substances such as those found in tobacco smoke ([@bb0150]). Each of these smoking measures were correlated with smoking pack years (Supplementary Fig. 8), and with each other, but taken together, they provide platform-independent evidence that the NSD1-Smoking and Stem-like-Smoking subtypes are smoking related, and driven by smoking-related damage.

Conversely, the Non-CIMP-Atypical and CIMP-Atypical subtypes, but particularly the CIMP-Atypical subtype, had low levels of all smoking related measures that were more similar to the HPV + subtype, which is not primarily caused by smoking ([@bb0500]). Consistent with clinical descriptions of atypical HNSCC ([@bb0480], [@bb0340], [@bb0495]), the CIMP-Atypical and Non-CIMP-Atypical subtypes were overrepresented for female patients (Supplementary Fig. 9, [Table 1](#t0005){ref-type="table"}), and were enriched for OSCC (Primarily oral tongue and oral cavity), while the NSD1-Smoking and Stem-like-Smoking subtypes comprised of approximately equal numbers OSCC and laryngeal squamous cell carcinoma (LSCC) (Supplementary Fig. 4). Importantly, the differential distributions of these smoking-related features between subtypes were consistent in OSCC and LSCC analyzed separately ([Supplementary Table 3](#ec0020){ref-type="supplementary-material"}), indicating that the degree of smoking-relatedness of subtypes is not simply driven by the proportions of different anatomic subsites.

Taken together, these findings indicate that our HPV − MethylMix subtypes differ in their degree of smoking-relatedness, and that the CIMP-Atypical subtype particularly matches the profile of atypical HNSCC.

3.5. DNA methylation profiles of MethylMix subtypes {#s0090}
---------------------------------------------------

We next investigated the general patterns of DNA methylation perturbation that define each MethylMix subtype. These subtypes differed greatly in their average numbers of hypermethylated and hypomethylated genes ([Fig. 3](#f0015){ref-type="fig"}). The NSD1-Smoking subtype had a significantly higher number of hypomethylated genes than other subtypes, but the lowest number of hypermethylated genes. Conversely, the CIMP-Atypical subtype had a strikingly higher number of hypermethylated genes and lower number of hypomethylated genes compared with all other subtypes. The degree of hypermethylation in the CIMP-Atypical subtype was consistent when OSCC and LSCC were analyzed separately ([Supplementary Table 3](#ec0020){ref-type="supplementary-material"}).

MethylMix 'genes' comprise clusters of concordantly methylated neighboring CpG sites. The proportion of hypermethylated CpG sites that were within CpG islands was highest in the NSD1-Smoking and CIMP-Atypical subtypes, while the proportion of hypomethylated CpG sites within CpG islands was highest in the HPV + subtype ([Fig. 3](#f0015){ref-type="fig"}c), suggesting different epigenetic mechanisms that define DNA methylation landscapes within different subtypes. The methylation profile of the CIMP-Atypical subtype, i.e., a strongly elevated number of hypermethylated CpG islands, matches the description of the 'CpG island methylator phenotype' (CIMP) ([@bb0275], [@bb0585]). CIMP defines clinically distinct subtypes in other cancers ([@bb0275]), and can be caused by various factors such as oncogenic viruses or IDH1/IDH2 mutations ([@bb0615], [@bb0175]), however CIMP is not well characterized in HNSCC. We found that the degree of CIMP, i.e., the overall number of hypermethylated CpG sites, was correlated with increasing age (Supplementary Fig. 10), suggesting that it is caused by age-related epigenetic instability, an etiological factor that increases with age, or increasing duration of exposure to a given cause.

3.6. Somatic mutation profiles differ between smoking-related and atypical HNSCC subtypes {#s0095}
-----------------------------------------------------------------------------------------

We next assessed the distribution of significantly mutated genes within our MethylMix subtypes. Of all genes, NSD1 mutations were most significantly differentially distributed between MethylMix subtypes (p = 2.2e − 16), occurring almost exclusively within the hypomethylated NSD1-Smoking subtype (Supplementary Fig. 5, [Supplementary Table 4](#ec0025){ref-type="supplementary-material"}), consistent with our previous report ([@bb0205]). Our NSD1-Smoking subtype corresponding to the H3K36me-impared subtype of HNSCC reported by [@bb0470]. Thirty percent of patients within the CIMP-Atypical subtype featured CASP8 mutations, compared with 0--7% in other subtypes, a highly significant enrichment (Supplementary Fig. 5). Mutations in HRAS, a gene co-muted with CASP8, and NOTCH1, were also significantly enriched in the CIMP-Atypical subtype, though HRAS was only mutated in 8/66 (12%) of CIMP-Atypical subtype patients with mutation data. CASP8 and NOTCH1 mutations that were not in the CIMP-Atypical subtype were mostly found in the Non-CIMP-Atypical subtype, suggesting that they may be related to atypical, rather than smoking or HPV-related HNSCC etiology.

3.7. Driver copy number aberrations lacking in the CIMP-Atypical subtype {#s0100}
------------------------------------------------------------------------

Given the depletion of CNAs in atypical MethylMix subtypes relative to smoking-related subtypes, we assessed the distribution between subtypes of frequent driver CNA events that were previously described in the TCGA patient cohort ([@bb0355]) (namely 3q26.33, 5p12, 8q11.21 and 8q24.21 amplifications, and 3p12.1, 3p24.1 and 8p23.2 deletions). The CIMP-Atypical subtype had fewer 5p12 amplifications, 3p12.1 deletions, and 3p24.1 deletions than other HPV − subtypes (Supplementary Fig. 11), indicating that this subtype lacks CNAs that are frequent in HNV − HNSCC, but lacking in more genomically stable HPV + HNSCC. Notably, the CIMP-Atypical subtype was depleted for 3q26.33 amplifications, among the most frequent and well studied focal CNA event in HNSCC ([@bb0395]), compared with all (both HPV + and HPV −) subtypes (Supplementary Fig. 11). 3q26.33 encompasses SOX2, a major oncogenic driver of stem-like gene expression in SCC ([@bb0395], [@bb0055], [@bb0325]).

Intriguingly, SOX2 amplifications co-occurred with DNA hypomethylation of a region of the SOX2 overlapping transcript (SOX2OT) ([Fig. 4](#f0020){ref-type="fig"}a), lying adjacent to a SOX upstream enhancer ([@bb0080]). This SOX2OT region was hypomethylated in most patients within smoking-related and HPV + subtypes, but hypermethylated in atypical HNSCC subtypes (Supplementary Fig. 12).

SOX2 amplification and SOX2OT methylation were each independently associated with expression of SOX2 (Supplementary Fig. 13a), SOX2 target genes, i.e., genes whose promoters were bound by SOX2 in human embryonic stem cells (ESCs) ([@bb0360]) ([Fig. 4](#f0020){ref-type="fig"}b), and ESC marker genes ([@bb0020]) (Supplementary Fig. 13b). Expression of SOX2 (Supplementary Fig. 13c), and both of these gene sets was lowest in the CIMP-Atypical subtype (Supplementary Figs. 4b and 13d, [Fig. 5](#f0025){ref-type="fig"}c). Taken together, these findings indicate that the CIMP-Atypical HNSCC subtype lacks both mechanisms that drive SOX2 overexpression in other HNSCC subtypes, that results in more stem-like transcriptional identity.

Expression of these SOX2 target and ESC marker gene sets was associated with a more undifferentiated state in breast and other cancer types ([@bb0045]). Consistently, we found that mean expression of SOX2 target genes is correlated with increasing pathological grade ([Fig. 4](#f0020){ref-type="fig"}d), and that the CIMP-Atypical included a higher frequency of well-differentiated HNSCCs than other subtypes (Supplementary Fig. 14).

3.8. The CIMP-Atypical subtype features an antiviral gene expression signature {#s0105}
------------------------------------------------------------------------------

In order to identify potential driver pathways and etiological factors associated with the CIMP-Atypical subtypes, we identified genes overexpressed in the CIMP-Atypical subtype ([Supplementary Table 5](#ec0030){ref-type="supplementary-material"}), and performed gene expression enrichment analysis (GSEA) to identify gene sets that significantly overlapped with these genes. The most enriched gene sets represented genes that are activated by type I and II interferons (IFNs), i.e. genes activated during interferon-mediated innate immune response to viral or other pathogen infection ([Supplementary Table 6](#ec0035){ref-type="supplementary-material"}).

A network map illustrating the top 100 most overexpressed gene sets revealed a dense cluster of partially redundant enriched gene sets ([Fig. 5](#f0025){ref-type="fig"}a). Three of the top five hub gene sets, i.e., gene sets with the highest number of edges/mutually overlapping genes between gene sets, represented IFNα responsive genes: These included sets of genes upregulated by treatment with IFNα in ovarian cancer side-population cells ([@bb0450]), primary fibroblasts ([@bb0065]), and primary hepatocytes ([@bb0505]). Curiously, although the CIMP-Atypical subtype was not associated with any known oncogenic virus (see above, Supplementary Fig. 3), most of these enriched gene sets represent interferon-inducible antiviral response gene sets. The CIMP-Atypical gene expression signature is also remarkable similar to the set of genes upregulated by expression of double-stranded RNA (dsRNA) derived from reactivated endogenous retroviruses (ERVs), as a result of inhibition of DNA methylation in cancer ([@bb0095], [@bb0510]). Indeed, all of the IFN-inducible genes upregulated by DNA methylation inhibition in ovarian cancer ([@bb0095]) were upregulated in the CIMP-Atypical subtype (Supplementary Fig. 15).

The co-occurrence of IFN responsive gene overexpression and CASP8 mutations within the CIMP-Atypical subtype is intriguing, as CASP8 initiates apoptosis in response to type I and II interferon-mediated signaling ([@bb0435], [@bb0310], [@bb0475], [@bb0580]). CASP8 was the only significantly mutated gene associated with an IFN response signature (the top hub enriched gene set ([@bb0450])) ([Fig. 5](#f0025){ref-type="fig"}b), and is therefore uniquely related to IFN response in HNSCC.

Immune gene expression signatures in solid tumors typically reflect the distribution of tumor infiltrating leukocytes (TALs) within the tumor ([@bb0190]). To gain insight into the immune transcriptional profile of the CIMP-Atypical subtype, we inferred the levels of specific immune cell types within each TCGA patient using CIBERSORT ([@bb0455]). Patients of the CIMP-Atypical subtype were enriched for pro-inflammatory M1 macrophages ([Fig. 5](#f0025){ref-type="fig"}c, [Supplementary Table 7](#ec0040){ref-type="supplementary-material"}), consistent with upregulation of IFN responsive genes, as M1 macrophages are activated by IFNγ, and M1 activation or 'polarization' induces upregulation of many IFN responsive genes ([@bb0265], [@bb0405]).

The CIMP-Atypical subtype also featured elevated levels of CD8 positive (CD8 +) T cells ([Fig. 5](#f0025){ref-type="fig"}c, [Supplementary Table 7](#ec0040){ref-type="supplementary-material"}), a marker of anti-cancer immune response, and a favorable prognostic marker in HNSCC ([@bb0030]), compared with other HPV − subtypes, and almost as high as the HPV + subtype.

As MethylMix filters differentially methylated genes to include only those at which methylation is associated with gene expression, the CIMP-Atypical subtype featured an elevated number of epigenetically silenced genes.

GSEA did not reveal any consistent themes among genes downregulated of hypermethylated in the CIMP-Atypical subtype (data not shown), suggesting that CIMP does not selectively silence any particular class of genes. However, genes that were downregulated and/or hypermethylated in the CIMP-Atypical subtype included tumor suppressor genes listed by TSgene ([@bb0665]) and genes that are causally implicated in cancer, listed within COSMIC cancer Gene Census ([@bb0185]) ([Supplementary Table 8](#ec0045){ref-type="supplementary-material"}), indicating that CIMP alters cancer gene expression pathways.

3.9. Validation of the CIMP-Atypical subtype {#s0110}
--------------------------------------------

Overall, our findings indicate that the CIMP-Atypical subtype is clinically atypical and molecularly distinct, and may therefore represent a distinct etiological and clinical entity. We therefore focused on validating this subtype in independent patient cohorts. We developed a gene expression classifier using prediction of microarrays (PAM) analysis ([@bb0595]) to predict the CIMP-Atypical subtype based on gene expression data, and tested the ability of this model to classify the CIMP-Atypical subtype using 100-fold cross validation within the training (TCGA) data set. This classifier could classify the CIMP-Atypical subtype with an area under the curve (AUC) of 0.92 (95% confidence interval 0.89--0.94) (Supplementary Fig. 16). The genes used by the model to classify the CIMP-Atypical subtype were highly consistent across folds of cross-validation, and included 10 upregulated and 22 downregulated genes (in the CIMP-Atypical subtype relative to other subtypes) that were consistently used across all cross-validation folds ([Supplementary Table 9](#ec0050){ref-type="supplementary-material"}). The upregulated genes generally comprised of IFN responsive genes, and included notable TAM expressed genes with important functions related to tumor-immune interactions, including VEGFC ([@bb0525]), CD274 (PD-L1) ([@bb0520]), and PDCD1LG2 (PD-L2) ([@bb0660]).

We then applied this classifier to the two largest independent patient cohorts with gene expression and relevant clinical data, GSE65858 (n = 253) ([@bb0640]) and GSE39366 (n = 138) ([@bb0630]). We found that 11% (28/253) patients within GSE65858, and 59% (81/138) patients within GSE39366, were predicted as the CIMP-Atypical subtype. Patients predicted as CIMP-Atypical were overrepresented for HPV − cancers, females, and OSCCs in both validations sets ([Fig. 6](#f0030){ref-type="fig"}, [Supplementary Table 10](#ec0055){ref-type="supplementary-material"}). Within HPV − HNSCCs (to exclude confounding by HPV status), patients predicted as CIMP-Atypical were overrepresented for non-smokers in both data sets ([Fig. 6](#f0030){ref-type="fig"}a, [Supplementary Table 10](#ec0055){ref-type="supplementary-material"}). In GSE39366 (for which differentiation status data were available), patients predicted as the CIMP-Atypical subtype were more likely to be 'well-differentiated', consistent with enrichment of grade 1 tumors in this subtype in the TCGA study ([Supplementary Table 10](#ec0055){ref-type="supplementary-material"}, [Fig. 6](#f0030){ref-type="fig"}a, Supplementary Fig. 14). Thus, these findings demonstrate that the gene expression signature of the CIMP-Atypical subtype can robustly classify atypical HNSCC patients. Finally, we confirmed that the IFNα response gene expression signature ([@bb0450]) (the top hub gene set enriched in the CIMP-Atypical subtype) was higher in atypical HNSCCs than smoking-related (HPV −) HNSCCs in GSE39366 and GSE65858 (Supplementary Fig. 17), though this only reached statistical significance in GSE39366.

3.10. Genes associated with atypical OSCC are consistent with a previous study {#s0115}
------------------------------------------------------------------------------

To further validate the CIMP-Atypical subtype, we examined a previously reported set of genes that were differentially expressed in non-smoking, non-alcohol related HNSCC relative to smoking and alcohol related HNSCC ([@bb0155]) including 28 upregulated, and 21 downregulated genes. This study included only OSCC and oropharyngeal HNSCCs, sites primarily associated with HPV − HNSCC; therefore these gene signatures were considered putative atypical signatures: We confirmed this by validating these signatures as associated with atypical HNSCC within the TCGA, GSE65858, and GSE39366 studies (Supplementary Fig. 18).

Next, Mean expression of the upregulated and downregulated genes was found to be significantly higher and lower, respectively, in the CIMP-Atypical subtype, compared with all other subtypes ([Fig. 6](#f0030){ref-type="fig"}b), and this was consistent in OSCC and LSCC analyzed separately ([Supplementary Table 11](#ec0060){ref-type="supplementary-material"}). This confirms the existence of gene expression patterns reproducibly associated with atypical HNSCC, and indicates that such expression patterns pertain particularly to the CIMP-Atypical HNSCC subtype.

4. Discussion {#s0120}
=============

Herein, we confirmed our previous finding of five HNSCC MethylMix subtypes ([@bb0205]), now within the complete TCGA HNSCC data set. These MethylMix subtypes segregated with HPV status and smoking, the best-known risk factors for HNSCC, indicating that they represent biologically meaningful subtypes.

HPV + HNSCCs clustered into a single, almost ubiquitously HPV + MethylMix subtype, agreeing with previous studies reporting a clear HPV DNA methylation signature ([@bb0375], [@bb0010]). Moreover, our MethylMix subtypes segregated with HPV status more perfectly than gene expression subtypes, consistent with previous reports that HPV + HNSCCs occur in two gene expression subtypes ([@bb0320]), or make up a subset of the AT expression subtype ([@bb0100], [@bb0355]). This provided proof of principle that our MethylMix subtypes capture key etiological heterogeneity in HNSCC, as HPV + HNSCC is known to be a clinically and biologically distinct subtype ([@bb0535], [@bb0500]). The original TCGA paper ([@bb0355]), and other reports ([@bb0530]); ([@bb0355]) have focused on molecular differences between HPV + and HPV − HNSCC, while Lleras et al. described DNA methylation features of HPV + HNSCC ([@bb0375]). Therefore, we took advantage of the segregation of HPV + from HPV − HNSCC in our study to investigate less well-studied heterogeneity within the four HPV − subtypes.

Overall, our findings indicate that smoking is a major driver of molecular heterogeneity in HNSCC, as two HPV − subtypes were clearly more smoking-related, indicated by smoking behavior measures (smoking status, pack years), rates of smoking-related genetic damage (smoking mutation signatures, copy number aberration rate), and expression of xenobiotic response genes as a measure of cellular response to smoking.

Smoking mutation signatures provide a long-term historical record of damage caused by smoking, the primary mutagen in HNSCC, as these signatures are elevated in cancers of former smokers ([@bb0565], [@bb0305]). These smoking measures are correlated, but capture different facets of smoking as it relates to cancer, including exposure level and levels of biological response to smoking.

The major difference between the two smoking-related subtypes was a striking enrichment for NSD1 mutations in one subtype, associated with widespread DNA hypomethylation. This agrees with previous findings by ourselves and others in a subset (n = 258) of the cohort used here ([@bb0355], [@bb0205]). Papillon-Cavanagh have recently reported on the NSD1 inactivated HNSCC subtype, which also features mutations in K36M-encoding mutations in histone 3 genes, and is defined by impairment of histone 3 lysine 36 (H3K36) methylation ([@bb0470]).

Two MethylMix subtypes lacked the classic risk factors, i.e., they were HPV −, yet had levels of smoking-related measures similar to the HPV + HNSCC. These subtypes comprised mostly OSCCs and had an overrepresentation of female patients, matching the clinical description of elusive atypical HNSCC ([@bb0090], [@bb0600], [@bb0390], [@bb0480], [@bb0335], [@bb0340], [@bb0060], [@bb0445], [@bb0485]). Epidemiological evidence indicates that smoking is less of a risk factor for OSCC than it is for LSCC ([@bb0380], [@bb0385]). Consistent with this, we have found that LSCCs are primarily (though not exclusively) found in the smoking-related MethylMix subsets, while OSCCs are more heterogeneous and can be smoking-related, HPV-related, or atypical.

We named the more atypical of these subtypes the CIMP-Atypical subtype, due to its hypermethylated CpG island phenotype, among other distinguishing molecular features. A gene expression signature for this subtype was predictive of atypical HNSCC features in independent patient population data sets from two previous studies ([@bb0630], [@bb0640]). Moreover, the CIMP-Atypical subtype displayed differential expression of genes previously reported as markers of non-smoking, non-drinking OSCCs ([@bb0155]), that we found to be reproducibly associated with atypical HNSCC. This confirms that atypical HNSCCs display distinct gene expression patterns independent of anatomic subsite. These atypical gene expression patterns pertain particularly to the CIMP-Atypical subtype, rather than non-smoking-related HNSCC in general, as they were altered in the CIMP-Atypical subtype relative to other (HPV + and HPV −) non-smoking related subtypes.

CIMP is a driver of cancer development, conferring epigenetic silencing of tumor suppressor genes ([@bb0585], [@bb0250]). CIMP has rarely been reported in HNSCC ([@bb0275]) and only using methods based on methylation of a small panel of genes ([@bb0545]). CIMP implies a distinct etiological basis for this subtype, as CIMP marks clinically relevant etiological subtypes of other cancers and is caused by key oncogenic drivers, including oncogenic viruses ([@bb0085]); ([@bb0210]) and driver mutations affecting DNA demethylation ([@bb0275]).

Patients of the CIMP-Atypical subtype had few CNAs, in contrast with a previous report that oral tongue squamous cell carcinomas (OTSCC) of young non-smoking patients have similar CNA profiles to those of older smokers ([@bb0495]). We found that the CIMP-Atypical subtype had lower frequency of CNAs that occur in other HPV − subtypes and are also infrequent in HPV + HNSCC. Particularly interesting, however, was a low frequency of SOX2 amplifications within the CIMP-Atypical subtype compared with all other subtypes. SOX2 is a major driver of pluripotency in ESCs and its overexpression maintains a cancer stem cell-like cellular population in HNSCC and other cancers ([@bb0395], [@bb0055], [@bb0325]). SOX2 protein expression is reproducibly associated with poor prognosis and development of lymph node metastases in HNSCC ([@bb0140]). Previous studies have shown that SOX2 amplification and protein overexpression more frequently occurs in a smoking-related gene expression HNSCC subtype in independent patient populations ([@bb0320], [@bb0630]). We found that SOX2 amplifications co-occur with hypomethylation of SOX2OT, the long non-coding RNA that overlaps with SOX2 and positively regulates SOX2 expression ([@bb0540]), in both smoking and HPV + subtypes, driving overexpression of SOX2 and SOX2 target/ESC marker genes in these subtypes. SOX2OT hypomethylation has only been reported, to our knowledge, in systemic sclerosis ([@bb0005]), but SOX2OT overexpression in lung cancers promotes proliferation ([@bb0260]). The CIMP-Atypical subtype had lower frequency of both mechanisms driving SOX2 overexpression, apparently resulting in overall lower expression of SOX2 target and ESC marker genes. This may be a mechanism underlying lower pathological grade of the CIMP-Atypical subtype, as SOX2 target gene expression was associated with higher grade, as previously reported in other cancers ([@bb0045]), and SOX2 protein expression of was associated with pathological grade in a previous report ([@bb0225]).

The CIMP-Atypical subtype features a gene expression signature characteristic of IFN immune response, overlapping with multiple gene sets related to viral infection, and this signature was reproducibly associated with atypical HNSCC in independent patient population. IFNs are best known as mediators of innate immune response to pathogens ([@bb0035]), but play diverse roles in cancer. This interferon signature coincide with infiltration of pro-inflammatory M1 macrophages, typifying an inflammatory signature, as M1 macrophages are activated by IFNγ, and M1 macrophage polarization stimulates expression of IFN responsive genes ([@bb0265], [@bb0405]).

Tumor associated macrophages (TAMs) are broadly classified into pro-inflammatory M1 TAMs and anti-inflammatory M2 TAMs. While M2 TAMs are generally considered to be pro-oncogenic, M1 TAMs are considered anti-oncogenic, as they can kill tumor cells and oncogenic pathogens ([@bb0115], [@bb0465]). M1 TAMs co-occurred with CD8+ T lymphocytes in the CIMP-Atypical subtype, consistent with evidence that M1 TAMs stimulate activate CD8+ T cell immune response ([@bb0120], [@bb0145]). CD8+ T cells are the best known mediators of anti-cancer immune response, and CD8+ T cell levels are favorably prognostic in both HPV + and HPV − HNSCC ([@bb0030], [@bb0025]).

We have found evidence that CD8+ T cell response may be inhibited in the CIMP-Atypical subtype, however, as CD274 (PD-L1) and PDCD1LG2 (PD-L2), ligands for immune checkpoint receptor PD-1, were overexpressed. Binding of PD-L1 and PDCD1LG2 to PD-1 on T CD8+ T cells is well known to inhibit CD8+ T cell response ([@bb0660]; [@bb0520]).

PD-L1 is expressed on both tumor cells and TAMs ([@bb0520]), however we have recently show that M1 TAM levels are correlated with PD-L1 expression across multiple cancer types (Champion et al., Manuscript in preparation), suggesting that M1 TAMs represent an important source of PD-L1 expression in cancer. Given strong CD274 overexpression in CIMP-Atypical subtype, CIMP-Atypical HNSCCs may be uniquely sensitive to PD-1/PD-L1 checkpoint blockade.

Another key oncogene that is apparently expressed by M1 TAMs is VEGFC, which may contribute to metastasis by promoting lymphangiogenesis ([@bb0525]). Investigation of potential pro-tumorigenic roles of M1 TAMs in CIMP-Atypical HNSCC is therefore warranted.

The CIMP-Atypical subtype featured enrichment of mutations in CASP8, a frequently mutated gene in OSCC ([@bb0625], [@bb0565], [@bb0070]). This is consistent with a previous report that CASP8 mutations marked a HNSCC molecular subtype featuring few CNAs ([@bb0490]). CASP8 mutations reportedly driving growth, migration and invasion in HNSCC ([@bb0365]). CIMP in glioblastoma (G-CIMP) can be caused by IDH1 mutations ([@bb0235]). BRAF V600E mutations in colorectal cancer only found in cancers with CIMP, but approximately 50% of CIMP positive colorectal cancers have BRAF mutations, indicating that BRAF mutations are unlikely to cause CIMP ([@bb0255]). CASP8 mutations are less tightly associated with CIMP in HNSCC than either IDH1 or BRAF mutations in their respective cancers, occurring within 30% of the CIMP-Atypical subtype, while 26% of CASP8 mutations occurred in other subtypes, indicating that CASP8 mutations and CIMP are unlikely to be causally related. Nonetheless, the strong enrichment of CASP8 mutations in the CIMP-Atypical subtype suggests that they play a pathogenic role that is inherent to this subtype. We hypothesize that CASP8 mutations enable cell survival within the CIMP-Atypical subtype by blocking the normal apoptotic process induced by IFN signaling: IFNs induce apoptosis via the extrinsic pathway by activating the JAK-STAT pathway, in turn inducing expression and activation of *CASP8*/Caspase-8 [@bb0435], [@bb0310], [@bb0475]. Restoration of CASP8 function, or stimulation of its effectors may represent a therapeutic option for CASP8 inactivated HNSCCs.

The occurrence of an inflamed phenotype in CIMP-Atypical HNSCC raises the intriguing possibility that CIMP-Atypical HNSCC is caused by chronic inflammation: This corresponds to an emerging hypothesis that pathogen-related chronic inflammation causes some OSCCs, as periodontal disease is associated with increased OSCC incidence ([@bb0440], [@bb0590], [@bb0180], [@bb0160]). The inflammatory state may reflect innate immune response to an infectious agent that cause periodontal disease or oral inflammation ([@bb0635]), given the role of M1 macrophages and IFNs response to infection ([@bb0370], [@bb0415]). The notion that the CIMP-Atypical subtype may be caused by an infectious agent is further supported by the presence of CIMP, which is caused by viruses in some cancers ([@bb0375], [@bb0210], [@bb0425], [@bb0050]), and the low mutation burden, suggesting a non-carcinogenic origin. The IFN signature of the CIMP-Atypical subtype is strikingly similar to a reported 'interferon-inducible antiviral signature', caused by expression of double-stranded RNA (dsRNA) derived from reactivated ERVs as a result of inhibition of DNA methyltransferases in ovarian and colorectal cancer cell lines ([@bb0095]; [@bb0510]). Moreover, this ERV-induced signature is associated with the CIMP subtype of colorectal cancer ([@bb0510]). Given that many of the antiviral genes overexpressed in the CIMP-Atypical subtype, such as members of the 2′-5′-oligoadenylate synthase (OAS) family ([@bb0345]) and DDX58 ([@bb0285]), sense viral dsRNA, and the ancient role played by DNA methylation in regulation of ERVs ([@bb0560]), it seems plausible that reactivation of ERVs may explain the co-occurrence of CIMP and the anti-viral signature in the CIMP-Atypical subtype.

Whether the CIMP-Atypical antiviral signature reflects response to exogenous or endogenous retroviruses, other pathogens, or whether this signature reflects a more general IFN response to a non-pathogen stimulus such as age, obesity ([@bb0460]) or cancer itself, remain to be resolved by future molecular and epidemiological research.

Our findings provide conclusive evidence that atypical HNSCC is molecularly distinct from smoking and HPV-related HNSCC across multiple platforms/molecular levels, provide a molecular classification system for atypical HNSCC, and postulate that CIMP-Atypical HNSCC represents a distinct etiological and clinical entity. DNA methylation-based validation of the CIMP-Atypical subtype in independent patient cohorts is warranted, particularly as the DNA methylation signature may be used to develop molecular biomarkers to clinically diagnose and investigate CIMP-Atypical HNSCC.

The incidence of atypical OSCC in women appears to be rising, despite the decline of smoking-related HNSCC in males in western countries ([@bb0340], [@bb0060]). Identification of the etiological and molecular drivers of atypical subtypes, and development of appropriate prevention and treatment strategies, remain a priority.

The following are the supplementary data related to this article.Supplementary Fig. 1 Consensus plot indicating five DNA methylation clusters or subtypes: Visualization of consensus clustering ([@bb0645]) of 528 HNSCC patients into five clusters, with blue indicating high consensus and white indicating low consensus.Supplementary Fig. 2 Distribution of TCGA gene expression subtypes between MethylMix subtypes: Bar plot indicates the distribution of gene expression subtype assignments for 279 HNSCCs, derived from [@bb0355], between our five MethylMix subtypes.Supplementary Fig. 3 Distribution of patients with tumor viruses between MethylMix subtypes: Differential distribution of HPV16, HPV33, and other viruses, between MethylMix subtypes, using data derived from [@bb0575]. Viral infection status for infection was inferred based on detection of viral RNA in tumor RNA-Seq data.Supplementary Fig. 4 Distribution of HNSCC anatomic subsites between MethylMix subtypes: Bars indicate the percentages of HNSCCs within each anatomic subsite, for each MethylMix subtype separately.Supplementary Fig. 5 Differential distribution of point mutations in significantly mutated genes between MethylMix subtypes: Mutations shown include all genes that were significantly mutated in HNSCC (based on a MutSig DB report), and that were significantly differentially distributed between MethylMix subtypes (FDR corrected Pearson\'s chi-squared test p-value \< 0.05). Bars indicate the percentage patients with mutations in each subtype. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.Supplementary Fig. 6 Kaplan Meier survival curve indicating variability in survival between MethylMix subtypes: Prolonged overall survival in the HPV + subtype compared with other MethylMix subtypes, based on a chi-square statistic test for equality, with survival data censored at five years. \*\*p-value \< 0.001.Supplementary Fig. 7 Distribution of patients with human papilloma virus and other viral infections within TCGA gene expression subtypes: Differential distribution of HPV16, HPV33, and other viruses, between TCGA gene expression subtypes, based on expression subtype assignments derived from [@bb0355] and viral infection data based on detection of viral RNA in tumor RNA-Seq data, derived from [@bb0575].Supplementary Fig. 8 Correlation of smoking mutation signatures with smoking exposure measures: Smoking pack years were positively correlated with a) G \> T transversion rate, b) C \> A transversion rate c) mean xenobiotic metabolism gene expression and d) overall copy number aberration (CNA) rate. Regression lines, linear regression p-values, and spearman correlation coefficients (Rho) are indicated.Supplementary Fig. 9 Distribution of female patients between MethylMix subtypes.Supplementary Fig. 10 Correlation of the degree of CIMP with increasing age: Scatter plot indicating the correlation of the number of hypermethylated MethylMix genes per patient with age at cancer diagnosis. Regression line, linear regression p-value, and spearman correlation coefficients (Rho) are indicated.Supplementary Fig. 11 Frequency of common amplification and deletions in MethylMix subtypes: Frequency of 3q26.33 and 5qp12 amplifications, and 3p12.1 and 3p24.1 deletions within each subtype, represented by individual genes within each altered region (indicated in plot titles).Supplementary Fig. 12 Hypermethylation of SOX2OT in atypical MethylMix subtypes, and hypomethylated in a subset of smoking-related MethylMix subtypes: SOX2OT methylation was higher in HNSC tumor compared with normal adjacent tissue, in patients of the Non-CIMP-Atypical and CIMP-Atypical subtypes (Wilcoxon rank sum test). Mean SOX2OT methylation did not differ significantly between tumor and normal tissue for patients within the NSD1-Smoking and Stem-like-Smoking subtypes, as SOX2OT hypomethylation occurred in some patients, but SOX2OT methylation increased or remained stable in others, within these subtypes. Point colors indicate SOX2OT MethylMix DNA methylation states. \*\*p value \< 0.001.Supplementary Fig. 13 SOX2OT hypomethylation and SOX2 amplification associated with SOX2 expression in smoking and HPV-related HNSC subtypes: Expression of a) SOX2 and b) mean expression of embryonic stem cell (ESC) marker genes (indicated by blue horizontal lines) were higher in patients with SOX2 amplifications compared with patients with normal SOX2 copy number (Wilcoxon rank sum test). Both expression measures were negatively correlated with SOX2OT methylation in patients with SOX2 amplifications. Regression lines, linear regression p-values, and spearman correlation coefficients (Rho) are indicated. SOX2OT MethylMix methylation states are indicated by point colors. Expression of c) SOX2 and d) ESC marker genes was significantly lower in the CIMP-Atypical subtype (green) than smoking-related (olive & pink) and HPV + (blue) subtypes, but not atypical subtype 1 (red) (Wilcoxon rank sum test). \*\*\*p \< 0.001.Supplementary Fig. 14 Frequency of pathological grades in MethylMix subtypes. p-Values (Pearson\'s chi-squared test) for significance of differential distribution of grade 1 tumors between the CIMP-Atypical subtype and each other subtype are indicated. \*\*p \< 0.01.Supplementary Fig. 15 Expression of interferon-inducible genes upregulated by azacytidine treatment ([@bb0095]), within MethylMix subtypes. Scaled mean expression of Interferon-inducible viral defense genes that were upregulated by azacytidine treatment in ovarian cancer cell lines, within each MethylMix subtype.Supplementary Fig. 16 Performance of a gene-expression based supervised predictor in classifying the CIMP-Atypical subtype. ROC curve illustrating the performance of a gene-expression based supervised classifier in correctly classifying the CIMP-Atypical subtype, over 10 rounds of cross-validation within TCGA data. The classifier was determined using prediction of microarray (PAM) analysis ([@bb0595]), which were differentially expressed between the CIMP-Atypical subtype and other subtypes combined.Supplementary Fig. 17 Association of interferon response gene signature with atypical HNSCC in validation data sets. Mean expression (scaled) of an interferon response gene expression signature derived from [@bb0450] in atypical HNSCCs (HPV − non-smokers) and smoking-related HNSCCs (HPV − smokers) in two validation studies: GSE39366 ([@bb0630]) (n HPV − non-smoker = 18, n HPV − smoker = 96) and GSE65858 ([@bb0640]) (n HPV − non-smoker = 23, n HPV − smoker = 157).Supplementary Fig. 18 Validation of previously reported gene expression signatures associated with atypical HNSCC, in three independent patient populations. Mean expression (scaled) of genes reported as being significantly overexpressed and underexpressed in atypical HNSCC (non-smoking, non-drinking patients) relative to smoking and drinking HNSCC patients ([@bb0155]), was higher and lower, respectively in atypical HNSCC patients in the TCGA, GSE39366 ([@bb0630]) and GSE65858 ([@bb0640]) studies. The number of atypical (HPV negative (HPV −) non-smokers) and smoking related HNSCC patients (HPV − smokers) are: TCGA (n = 89 atypical, 161 smoking-related), GSE39366 (n = 18 atypical, 96 smoking-related), GSE65858 (n = 23 atypical, 157 smoking-related). Wilcoxon rank sum test p-values are indicated: \*p \< 0.05, \*\*\*p \< 0.001.Image 1Supplementary Table 1MethylMix driver genes in the TCGA HNSCC study.Supplementary Table 1Supplementary Table 2MethylMix subtypes and covariate data for TCGA HNSCC patients.Supplementary Table 2Supplementary Table 3Distribution of key clinical and etiological variables between MethylMix subtypes (OSCC and LSCC separately).Supplementary Table 3Supplementary Table 4Significantly mutated genes that are differentially distributed between MethylMix subtypes.Supplementary Table 4Supplementary Table 5Genes upregulated and downregulated in the CIMP-Atypical subtype relative to other MethylMix subtypes.Supplementary Table 5Supplementary Table 6Gene sets (GSEA) enriched in genes overexpressed in the CIMP-Atypical subtype.Supplementary Table 6Supplementary Table 7Relative inferred levels of tumor infiltrating leukocyte (TAL) types in MethylMix subtypes.Supplementary Table 7Supplementary Table 8Tumor suppressor and cancer mutated genes hypermethylate and/or downregulated within the CIMP-atypical subtype.Supplementary Table 8Supplementary Table 9Genes stably used by the PAM classifier to classify the CIMP-Atypical subtype across all 100 folds of cross validation.Supplementary Table 9Supplementary Table 10Validation of clinical attributes of the CIMP-Atypical subtype in two validation gene expression cohorts.Supplementary Table 10Supplementary Table 11Levels of Farshadpour atypical HNSCC gene expression signatures ([@bb0155]) in MethylMix subtypes (OSCC and LSCC separately).Supplementary Table 11
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![Heatmap indicating differential methylation and distribution of key etiological and molecular factors between MethylMix subtypes. MethylMix subtypes identified by consensus clustering of abnormally methylated genes, identified using MethylMix ([@bb0200]). 'Smokers' refers to current or reformed former smokers (\< 15 years). OSCC: oral squamous cell carcinoma.](gr1){#f0005}

![Differential distribution of smoking measures between MethylMix subtypes. Distribution of a) smoking status categories (Pearson\'s chi-squared test), b) smoking mutation signature rates (overall number of G \> T and C \> A transversions per individual) (Wilcoxon rank sum test, p-values are shown for C \> A and G \> T mutations signatures separately), c) copy number aberration rate (Wilcoxon rank sum test) and d) mean expression of xenobiotic metabolism genes (Wilcoxon rank sum test), between MethylMix subtypes. p-Values indicate significance of the differences in smoking variables between the CIMP-Atypical subtype (green) and each other subtype separately. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](gr2){#f0010}

![Different aberrant DNA methylation profiles associated with MethylMix subtypes. Variation in the mean number of a) hypermethylated and b) hypomethylated MethylMix genes per patient, between MethylMix subtypes, with a significantly higher number of hypermethylated genes, and lower number of hypomethylated genes in the CIMP-Atypical subtype (green) compared with each other subtype (Wilcoxon rank sum test). c) The proportion of CpG sites in hypermethylated genes that were within CpG islands was highest within the NSD1-Smoking (olive) and CIMP-Atypical (green) subtypes, while the number of hypomethylated CpG sites within CpG islands was highest within the HPV + subtype (blue). \*\*\*p \< 0.001.](gr3){#f0015}

![SOX2OT hypomethylation and SOX2 amplifications drive SOX2 pathway expression, and are lacking in the CIMP-Atypical subtype. a) i) Mixture model plot indicating two abnormal SOX2OT DNA methylation states. Histogram illustrates the frequency of patients at levels of SOX2OT methylation in tumor. DNA methylation states (mixture model components) include a hypomethylated and hypermethylated state in tumor, indicated by red and green curves, respectively. The 95% confidence interval for the range of SOX2OT methylation in normal adjacent tissue is indicated by the black horizontal bar. ii) The SOX2OT hypomethylated state occurred in only one patient within the CIMP-Atypical subtype, but occurred in 10--61% of patients in other subtypes. iii) The SOX2OT hypomethylated state (red) was more frequent among patients with either monoallelic ([@bb0555]) or biallelic ([@bb0040]) SOX2 amplifications, but did not differ between patients with SOX2 deletions and normal SOX2 copy number (Pearson\'s chi-squared test). b) Mean expression of SOX2 target genes (Blue horizontal line) was higher in patients with SOX2 amplifications compared with patients without SOX2 amplifications (Wilcoxon rank sum test), and was negatively correlated with SOX2OT methylation in both groups, indicating that both mechanisms contribute independently to SOX2-related transcription in HNSCC. Linear regression lines and p values, as well as Spearman correlation coefficients (rho) are indicated. SOX2OT MethylMix methylation states are indicated by point colors. c) Mean expression of SOX2 target genes, i.e., genes with promoters bound by SOX2 in embryonic stem cells (ESCs) ([@bb0360]) was lower in the CIMP-Atypical subtype compared with each other subtypes (Wilcoxon rank sum test). d) Mean expression of SOX2 target genes displays a stepwise increase with increasing pathologic grade (Wilcoxon rank sum test). \*\*p \< 0.01, \*\*\*p \< 0.001.](gr4){#f0020}

![The CIMP-Atypical subtype features an inflammatory gene expression signature. a) Network map illustrating enrichment for immune response genes among genes overexpressed in the CIMP-Atypical subtype. Nodes represent enriched gene sets and edges represent mutual overlap between gene sets, indicating redundancy between enriched gene sets. Hub gene sets, i.e., the top five gene sets with the highest number of edges are highlighted yellow. The top 100 gene sets identified by gene set enrichment analysis were included in the Network Map. b) Higher mean expression of a reported IFN response gene expression signature ([@bb0450]) in HNSCCs with CASP8 mutations, versus those without CASP8 mutations (Wilcoxon rank sum test). c) Levels of infiltrating M1 macrophages and CD8+ T cells, inferred using CIBERSORT ([@bb0455]) within MethylMix subtypes Wilcoxon rank sum test p values for difference in mean TAL levels between the CIMP-Atypical subtype and other subtypes are indicated. \*\*p \< 0.01, \*\*\*p \< 0.001.](gr5){#f0025}

![Validation of the CIMP-Atypical subtype gene expression signature. a) Differences in the distribution of clinical features that define the CIMP-Atypical subtype between patients within (red) or not within (grey) the CIMP-Atypical subtype in the TCGA cohort (shown for reference), and in within patients predicted as belonging to the CIMP-Atypical subtype (red) or not (grey), by a gene expression classifier, in two additional patient cohorts (GSE65858 ([@bb0640]), GSE39366 ([@bb0630])). There was a higher percentage of non-smokers\* (never smokers or long-term reformed former smokers), female patients, OSCCs and well-differentiated/pathologic grade 1 tumors, among patients predicted as belonging to the CIMP-Atypical subtype. Pearson\'s chi-squared p values are indicated. b) Mean expression of genes reported as i) upregulated and ii) downregulated, in atypical HNSCC compared with typical HNSCC (smoking and alcohol-associated) ([@bb0155]), was significantly higher and lower, respectively, within the CIMP-Atypical subtype (green) compared with within each other subtype (Wilcoxon rank sum test).\
\*Difference in the proportion of non-smokers was restricted to HPV − HNSCCs only, as HPV + HNSCC are frequently non-smokers.\
Abbreviations for anatomic subsites: Oral squamous cell carcinoma (OSCC), hypopharyngeal squamous cell carcinoma (HSCC), laryngeal squamous cell carcinoma (LSCC), oropharyngeal squamous cell carcinoma (OPSCC), base of tongue (BT), tonsil (T) lip (L). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](gr6){#f0030}

###### 

Distribution of key clinical and etiological variables between MethylMix subtypes.

Table 1

                                                                                           MethylMix subtype                                                                                                                                        
  ---------------------------------------------------------------------------------------- -------------------------- --------------------------------- --------------------------------- -------------------------- ------------------------------ ---------------------------------
  Smoking status (n (%))                                                                   Never                      34 (29%)                          6 (10%)                           28 (29%)                   18 (39%)                       10 (11%)
  Former \> 15 years                                                                       17 (15%)                   6 (10%)                           24 (25%)                          5 (11%)                    11 (12%)                       
  Former \< 15 years                                                                       32 (27%)                   16 (27%)                          17 (18%)                          12 (26%)                   33 (35%)                       
  Current                                                                                  34 (29%)                   31 (53%)                          27 (28%)                          11 (24%)                   39 (42%)                       
  p-Values[a](#tf0005){ref-type="table-fn"}                                                0.162                      \< 0.001                          --                                0.775                      \< 0.001                       
  HPV status (n (%))                                                                       HPV −                      81 (99%)                          44 (100%)                         63 (98%)                   1 (3%)                         72 (92%)
  HPV16                                                                                    0 (0%)                     0 (0%)                            0 (0%)                            32 (89%)                   5 (6%)                         
  HPV33                                                                                    1 (1%)                     0 (0%)                            1 (2%)                            3 (8%)                     1 (1%)                         
  p-Values[b](#tf0010){ref-type="table-fn"}                                                1                          1                                 --                                \< 0.001                   0.197                          
  Gender (n (%))                                                                           F                          45 (37%)                          12 (20%)                          42 (43%)                   5 (11%)                        18 (19%)
  M                                                                                        77 (63%)                   49 (80%)                          56 (57%)                          41 (89%)                   77 (81%)                       
  p-Values[c](#tf0015){ref-type="table-fn"}                                                0.446                      0.005                             --                                \< 0.001                   \< 0.001                       
  Anatomic subsite (n (%))                                                                 Base of tongue             4 (3%)                            2 (3%)                            1 (1%)                     11 (24%)                       4 (4%)
  Hypopharynx                                                                              2 (2%)                     0 (0%)                            1 (1%)                            1 (2%)                     2 (2%)                         
  Larynx                                                                                   15 (12%)                   27 (44%)                          7 (7%)                            1 (2%)                     44 (46%)                       
  Lip                                                                                      1 (1%)                     0 (0%)                            0 (0%)                            0 (0%)                     1 (1%)                         
  Oral                                                                                     94 (77%)                   31 (51%)                          89 (91%)                          8 (17%)                    44 (46%)                       
  Tonsil                                                                                   6 (5%)                     1 (2%)                            0 (0%)                            25 (54%)                   0 (0%)                         
  p-Values[d](#tf0020){ref-type="table-fn"}                                                0.011                      \< 0.001                          --                                \< 0.001                   \< 0.001                       
  Pathological grade (n (%))                                                               1                          15 (12%)                          5 (8%)                            20 (21%)                   1 (2%)                         5 (6%)
  2                                                                                        82 (68%)                   39 (65%)                          59 (61%)                          15 (37%)                   60 (67%)                       
  3                                                                                        23 (19%)                   16 (27%)                          18 (19%)                          19 (46%)                   24 (27%)                       
  4                                                                                        0 (0%)                     0 (0%)                            0 (0%)                            6 (15%)                    1 (1%)                         
  p-Values[e](#tf0025){ref-type="table-fn"}                                                0.152                      0.069                             --                                0.014                      0.005                          
  Age (mean (IQR)) p-value[f](#tf0030){ref-type="table-fn"}                                                           61 (52--70) p = 0.406             58 (52--65) p = 0.016             63 (53--73)                56 (50--62) p = 0.002          63 (56--68) p = 0.947
  Overall mutation burden (mean (IQR)) p-value[f](#tf0030){ref-type="table-fn"}                                       124 (62--115) p = 0.08            188 (97--252) p = 0.004           114 (695--145)             99 (38--117) p = 0.004         
  Smoking mutation rates (mean (IQR)) p-value[f](#tf0030){ref-type="table-fn"}             G \> T transversions       7 (3--9) p = 0.574                24 (6--34) p ≤ 0.001              6 (3--8)                   5 (2--5) p = 0.037             17 (5--20) p ≤ 0.001
  C \> A transversions                                                                     7 (3--8) p = 0.875         25 (6--36) p ≤ 0.001              7 (4--9)                          4 (1--7) p = 0.003         17 (5--21) p = 0.002           
  \# CNAs (mean (IQR)) p-value[f](#tf0030){ref-type="table-fn"}                            CNAScore                   10,420 (6145--14,060) p ≤ 0.001   11,850 (8055--15,560) p ≤ 0.001   6805 (2550--9738)          6838 (3886--8006) p = 0.294    11,550 (8476--15,680) p ≤ 0.001
  Xenobiotic metabolism expression (mean (IQR)) p-value[f](#tf0030){ref-type="table-fn"}                              − 0.3 (− 0.8--0.1) p ≤ 0.001      0.8 (0.2--1.3) p ≤ 0.001          0                          0.2 (− 0.2--0.6) p ≤ 0.001     0.6 (0.1--1.2) p ≤ 0.001
  Abnormally methylated genes (mean (IQR)) p-value[f](#tf0030){ref-type="table-fn"}        \# hyper genes             954 (878--1033) p ≤ 0.001         724 (621--804) p ≤ 0.001          1282 (1184--1362)          866 (736--943) p ≤ 0.001       760 (674--850) p ≤ 0.001
  \# hypo genes                                                                            422 (384--461) p ≤ 0.001   587 (542--627) p ≤ 0.001          370 (344--394)                    462 (424--496) p ≤ 0.001   439 (380--494) p ≤ 0.001       
  IFN gene expression (mean (IQR)) p-value[f](#tf0030){ref-type="table-fn"}                                           0.2 (− 0.4--0.9) p ≤ 0.001        − 0.4 (− 1.1--0.4) p ≤ 0.001      0.8 (0.3--1.3)             − 0.2 (− 0.5--0.3) p ≤ 0.001   − 0.6 (− 1.2--0.1) p ≤ 0.001

Pearson chi-squared test for difference in distribution of non-smokers (never or former \> 15 years) between CIMP-Atypical subtype and other subtypes.

Pearson chi-squared test for difference in distribution of HPV − patients between CIMP-Atypical subtype and other subtypes.

Pearson chi-squared test for difference in distribution of female patients between CIMP-Atypical subtype and other subtypes.

Pearson chi-squared test for difference in distribution of OSCC patients between CIMP-Atypical subtype and other subtypes.

Pearson chi-squared test for difference in distribution of grade 1 cancers between CIMP-Atypical subtype and other subtypes.

Wilcoxon rank sum test for mean difference in continuous variable between CIMP-Atypical subtype and other subtypes.
